gms | German Medical Science

61st Annual Meeting of the German Society of Neurosurgery (DGNC) as part of the Neurowoche 2010
Joint Meeting with the Brazilian Society of Neurosurgery on the 20 September 2010

German Society of Neurosurgery (DGNC)

21 - 25 September 2010, Mannheim

Article

Send article

The immunogenic effect of 5-ALA-Photodynamic Therapy

Meeting Abstract

Search Medline for

  • Nima Etminan - Klinik für Neurochirurgie, Heinrich-Heine-Universität, Düsseldorf, Germany
  • Corinna Peters - Klinik für Neurochirurgie, Institut für Transplantationsdiagnostik and Zelltherapeutika, Heinrich-Heine-Universität, Düsseldorf, Germany
  • Walter Stummer - Klinik für Neurochirurgie, Klinik für Neurochirurgie, Universitätsklinikum Münster, Germany
  • Hans-Jakob Steiger - Klinik für Neurochirurgie, Heinrich-Heine-Universität, Düsseldorf, Germany
  • Rüdiger Volker Sorg - Institut für Transplantationsdiagnostik and Zelltherapeutika, Heinrich-Heine-Universität, Düsseldorf, Germany

Deutsche Gesellschaft für Neurochirurgie. 61. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC) im Rahmen der Neurowoche 2010. Mannheim, 21.-25.09.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. DocP1754

doi: 10.3205/10dgnc225, urn:nbn:de:0183-10dgnc2252

Published: September 16, 2010

© 2010 Etminan et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.

Outline

Text

Objective: 5-Aminolevulinic acid-mediated photodynamic therapy (ALA/PDT) can improve clinical outcome in patients suffering from glioblastoma multiforme (GBM). Due to the limited penetration of the laser light into brain tissue, however, additional mechanisms besides direct phototoxicity have to be involved in eliminating the more distant infiltrating tumor cells. Therefore the effect of ALA/PDT on the afferent phase of adaptive antitumoral-immunity was studied.

Methods: Human glioblastoma spheroids (U251, U87) were treated with ALA/PDT and the effect on the activity of human Dendritic cells (DC) was studied. Chemoattraction was studied using the Boyden-Chamber migration assay. Tumor material uptake was evaluated by flow cytometry, after CFSE-fluorescent labeling of tumor cells. The impact of ALA/PDT treated spheroids on DC maturation and function was studied in Co-cultures and quantified flowcytometrically and by determining the allo-stimulatory activity of the DC.

Results: ALA/PDT-treated glioma spheroids attract immature dendritic cells, whereas control spheroids did not display significant chemoattraction. The resulting vicinity of ALA/PDT-treated spheroids and DC allows effective uptake of tumor antigens. Even when control spheroids are cocultivated with DC, no significant uptake of tumor material was evident.

Moreover, ALA/PDT appears to generate immuno-stimulatory signals inducing DC maturation. CD83, CD80 and CD86 are significantly upregulated and an ALA/PDT-specific enhancement of T-cell stimulatory activity was observed.

Conclusions: ALA/PDT treatment of glioma spheroids stimulates the afferent phase of adaptive antitumoral-immunity, which may contribute to the beneficial effect of ALA/PDT treatment in patients with glioblastoma.